Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Monterizine in Asthma with Allergic Rhinitis
NCT02552667Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of montelukast + levocetirizine in asthma and allergic rhinitis (AR) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Mean Daytime Nasal Symptom Score. Started Sep 2014; status: completed.
02
Drugs
montelukast + levocetirizine
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02552667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02552667.